United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Archer-Daniels-Midland Company

Consolidated Water

Are you feeling the brunt of the market uncertainty in your retirement portfolio? Rebalancing your portfolio may be necessary at this stage.

Bullet Proof Your Portfolio: 3 Must-Have Defensive Stocks for 2023

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of its patients and other stakeholders. As a PBC, United Therapeutics is obligated to report its progress toward its public benef.

United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's business during a fireside chat session at the Morgan Stanley 21st Annual Global Healthcare Conference in New York City. The session will take place on Monday, September 11, 2023, from 12:55 p.m. to 1:25 p.m., Eastern Daylig.

United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

BioNTech SE

iShares Nasdaq Biotechnology ETF

The events of the last few years have made biotech investing look easier than it is. But, investing in biotech is not for the faint of heart.

The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023

United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's financial performance and cash flows indicate the potential for sustained high returns on operating capital employed. I am eyeing $273/share, or 12.6x forward P/E by FY'23 yearend.

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2023 Earnings Conference Call August 2, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Senior Vice President of Product Development Conference Call Participants Ash Verma - UBS Eun Yang - Jefferies Hartaj Singh - Oppenheimer Terence Flynn - Morgan Stanley Joseph Thome - TD Cowen Andreas Argyrides - Wedbush Operator Good morning, and welcome to the United Therapeutics Corporation Second Quarter 2023 Earnings Webcast. My name is Danielle, and I will be your conference operator today.

United Therapeutics Corporation (UTHR) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.41 per share. This compares to earnings of $2.41 per share a year ago.

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022. “I'm thrilled that United Therapeutics continues to report double-digit revenue growth and our highest quarterly revenue ever,” said.

United Therapeutics Corporation Reports Second Quarter 2023 Financial Results

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns.

If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023. United Therapeutics will host a public webcast Wednesday, August 2, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will.

United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc. The Federal Circuit affirmed that Liquidia's proposed Yutrepia™ product infringes a United Therapeutics' patent, U.S. Patent No. 10,716,793 (the '7.

United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, yesterday unveiled its new net zero energy distribution center located on the company's co-headquarters campus in Research Triangle Park, North Carolina. United Therapeutics Chairperson and CEO Dr. Martine Rothblatt welcomed North Carolina officials, members of the North Carolina General Assembly, and business leaders to a “cord cutting” ceremony to showcase the new distr.

United Therapeutics Unveils Net Zero Energy Distribution Center

Much of what the FTC attacks isn't anticompetitive, it's competitive. The most cynical anticompetitive acts coopt state mechanisms.

Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Pat Poisson - Executive Vice President of Technical Operations Leigh Peterson - Senior Vice President of Product Development Conference Call Participants Joseph Thome - TD Cowen and Company Hartaj Singh - Oppenheimer & Co. Jessica Fye - JPMorgan Eun Yang - Jefferies Andreas Argyrides - Wedbush Securities Ashwani Verma - UBS Operator Good morning, and welcome to the United Therapeutics Corporation First Quarter 2023 Earnings Webcast. My name is Danielle, and I will be your conference operator today.

United Therapeutics Corporation (UTHR) Q1 2023 Earnings Call Transcript

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings

United Therapeutics (UTHR) came out with quarterly earnings of $4.86 per share, beating the Zacks Consensus Estimate of $4.35 per share. This compares to earnings of $5.03 per share a year ago.

United Therapeutics (UTHR) Q1 Earnings Beat Estimates

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022. “The hard work and determination of our over 1,000 Unitherians during the first quarter of this year allowed us to reach over $500 mi.

United Therapeutics Corporation Reports First Quarter 2023 Financial Results

Amarin Corporation Plc

Corcept Therapeutics

Ionis Pharma

Pacira Pharmaceuticals

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be avail.

United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023

BeiGene

BioMarin Pharmaceutical

Incyte

argenx

Legend Biotech

Bio-Techne

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).

News for United Therapeutics Stock (UTHR)